Shingrix 治疗风湿病患者:双盲安慰剂对照 RCT
重组亚单位带状疱疹疫苗在接受免疫抑制或生物/靶向 DMARD 治疗的风湿性疾病患者中的安全性和免疫原性:一项双盲随机安慰剂对照试验
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies
研究概览
详细说明
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies.
Duration of study: 60 weeks
研究类型
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Hong Kong、中国
- Department of Medicine, Tuen Mun Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria for patients:
-
Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides
-
Age ≥18 years
-
Stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry:
- Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors
- Cyclophosphamide (intravenous pulses or daily oral)
- B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab)
- Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab
- Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab
- Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab
- The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib
-
Female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination
-
Willing to comply with all study procedures
Exclusion criteria for patients:
- Active infection, including upper respiratory tract infection
- Active HZ infection
- Active untreated tuberculosis
- HIV infection
- History of HZ or varicella vaccination in the past
- History of allergy to any vaccines
- Patients who are pregnant or plan to become pregnancy within one year of study entry
- Lactating women
- Patients who cannot give a written consent (mentally incapable or illiterate)
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:vaccine
Shingrix vaccine |
vaccine administration
其他名称:
|
|
安慰剂比较:placebo
normal saline injection (0.5mL) |
vaccine administration
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
humoral immune response to Shingrix
大体时间:week 12 (compared with baseline)
|
proportion of patients with 4x fold increase in anti-gE antibody titer |
week 12 (compared with baseline)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Humoral immune response
大体时间:week 52
|
proportion of patients with 4x fold increase in anti-gE antibody titer |
week 52
|
|
adverse events
大体时间:7 days after injection
|
solicited |
7 days after injection
|
|
adverse events
大体时间:4 weeks after injection
|
unsolicited |
4 weeks after injection
|
|
flares of underlying diseases
大体时间:week 26 and 60
|
disease flares |
week 26 and 60
|
|
herpes zoster infection
大体时间:week 60
|
herpes zoster infection |
week 60
|
|
cell mediated response to vaccine
大体时间:week 12 from baseline
|
in 40 patients (20 from each arm); number of IFNγ-secreting CD4+ T cell colonies on ELISPOT assay |
week 12 from baseline
|
合作者和调查者
调查人员
- 首席研究员:Chi Chiu Mok、Tuen Mun Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.